Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Trial status:Recruiting
Trial ID:
BNT327-06
NCT ID:
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting
Trial Details
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.
Medical Condition
Trial Drug
See more
Phase
Phase 2/Phase 3
Type
Interventional
Estimated Enrolment
982
Estimated Trial Date
Jan 2025 - Dec 2029
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
Alaska Oncology and Hematology, LLC
Anchorage, Alaska, United States, 99508
Status
Recruiting
Location
Clermont Oncology Center
Clermont, Florida, United States, 34711
Status
Recruiting
Location
Millennium Research and Clinical Development, LLC
Houston, Texas, United States, 77090
Status
Recruiting
Location
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Australia, 3199
Status
Recruiting
Location
ICON Cancer Care - Townsville
Hyde Park, Australia, 4812
Status
Recruiting
Location
Icon Cancer Centre Kurralta Park
Kurralta Park, Australia, 5037
Status
Recruiting